8 burning questions senators should ask Moderna’s Bancel

WASHINGTON — Moderna CEO Stéphane Bancel has some explaining to do.

Bancel will seem alone earlier than Sen. Bernie Sanders’ well being committee on Wednesday, the place he’ll need to defend his firm’s suggestion it can doubtless quadruple the worth of its Covid vaccines as soon as gross sales transition from bulk federal purchases to the open market.

The Senate listening to will likely be a watershed second for Bancel, a biotech celebrity cast in the course of the pandemic. Whereas Covid vaccine rival producer Pfizer is a longtime pharmaceutical behemoth with a large lobbying affect in Washington, in distinction, Moderna registered its first lobbyist in Washington in 2019 and its Covid-19 vaccine is its solely product in the marketplace.

Sanders, a Vermont Unbiased, has previously accused Bancel and Moderna’s different co-founders of profiteering off of taxpayer-funded analysis, since sides of the corporate’s strategy to creating its messenger RNA-based vaccine have been developed on the Nationwide Institute of Well being’s Vaccine Analysis Heart.

On the identical day the listening to was introduced, Moderna revealed plans to create a affected person help program to supply vaccines without charge to people who find themselves uninsured or underinsured. These with insurance coverage gained’t face out-of-pocket charges on the time they’re vaccinated, however the increased worth might effectively be mirrored in insurance coverage premiums.